4-Butoxy-2,6-dimethyl-anilin | 53985-00-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-Butoxy-2,6-dimethyl-anilin
• 英文别名: 4-Butyloxy-2,6-dimethyl-anilin；4-butoxy-2,6-dimethyl-phenylamine；4-butoxy-2,6-dimethylaniline
• CAS: 53985-00-5
• 化学式: C₁₂H₁₉NO
• 分子量: 193.289
• InChiKey: KIHUWAOTZVYMFH-UHFFFAOYSA-N

物化性质

• 沸点：
  156-157 °C(Press: 11 Torr)
• 密度：
  0.977±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Butoxy-2,6-dimethyl-anilin 在 sodium acetate trihydrate 作用下， 以 水 、 溶剂黄146 为溶剂， 以68.9 g (71.6%)的产率得到2-Bromo-4'-butoxy-2',6'-dimethyl propionanilide
  参考文献：
  名称：

  Synergistic local anesthetic compositions

  摘要：

  一种局部麻醉剂组合物，包括一种特定毒素，即河豚毒素或去氧河豚毒素，与另一种化合物混合在制药可接受的载体中，通常是传统的局部麻醉剂化合物或具有神经阻滞特性的类似化合物。

  公开号：

  US04022899A1
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 镍 作用下， 生成 4-Butoxy-2,6-dimethyl-anilin
  参考文献：
  名称：

  Überlokalanästhetischwirksame取代基二乙烯基氨基酰基苯胺衍生物

  摘要：

  Es wurden verschiedene同系物Reihen vonXylocain-ähnlichenLokalanästhetikahergestellt和auf i pharmakologischen Wirkungen untersucht。乙二氨基氨基-乙酰氨基苯酚-烷基醚和二乙氨基-乙酰氨基-甲苯基-烷基醚的合成和Wirkung的二元氨基-乙酰氨基-乙酰氨基-苯酚烷基酯和Wirkung的二氨基氨基-乙酰氨基-乙酰氨基酚烷基酯。在对苯二甲酰二乙酰氨基乙酰氨基苯酚烷基酚的合成中使用了甲基丙烯酸丁酯（Einfluss derEinführungvonEinführungvon Methylgruppen）。Dabei konnte beim二氨基氨基乙酰氨基-二甲苯醇-烷基酯，D Kombination der Strukturen des Xylocains和des Pacetacetins，Eine

  DOI：

  10.1002/hlca.19510340131

文献信息

• Pharmaceutical local anesthetic compositions
  申请人：Astra Pharmaceutical Products, Inc.

  公开号：US03957996A1

  公开（公告）日：1976-05-18

  A local anesthetic composition comprising a mixture in a pharmaceutically acceptable carrier of a particular toxin, namely, saxitoxin, and another compound, generally a conventional local anesthetic compound or a similar compound having nerve-blocking properties.

  一种局部麻醉剂组合物，包括一种特定毒素——腥毒素和另一种化合物，通常是传统的局部麻醉剂或具有神经阻滞特性的类似化合物，混合于药学上可接受的载体中。
• Primary aminoacylanilides
  申请人：Astra Pharmaceutical Products, Inc.

  公开号：US04237068A1

  公开（公告）日：1980-12-02

  Primary amino acylanilides of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, methyl, ethyl and propyl, R.sub.2 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.3 is selected from the group consisting of hydrogen and methyl, R.sub.4 is selected from the group consisting of hydrogen, methyl, and a C.sub.1 -C.sub.4 alkoxy group, R.sub.6 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.7 is hydrogen, methyl or ethyl, R.sub.8 is hydrogen, R.sub.9 is hydrogen, methyl or ethyl, R.sub.10 is hydrogen, and n is 0 or 1, with the provisions that (a) when n is 0, R.sub.8 can also be methyl; (b) when n is 1, and R.sub.7 is hydrogen, and R.sub.9 is hydrogen or methyl, then R.sub.10 can also be methyl; (c) when R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.6 is methyl, R.sub.7 is hydrogen, R.sub.8 is hydrogen, and n is 0, then R.sub.4 can be ethoxy or propoxy only; (d) when R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3, R.sub.4, R.sub.7 and R.sub.8 are hydrogen, and n is 0, then R.sub.6 is methoxy, ethoxy, or ethyl only; and the therapeutically acceptable salts thereof. Compounds of this type have been found to be effective longlasting cardiac antiarrhythmic agents, especially when administered by the oral route.

  式子为##STR1##的一级氨基苯甲酰胺，其中R.sub.1选自氢、甲基、乙基和丙基组成的群体，R.sub.2选自甲基、乙基、氯、甲氧基和乙氧基组成的群体，R.sub.3选自氢和甲基组成的群体，R.sub.4选自氢、甲基和C.sub.1-C.sub.4烷氧基组成的群体，R.sub.6选自甲基、乙基、氯、甲氧基和乙氧基组成的群体，R.sub.7为氢、甲基或乙基，R.sub.8为氢，R.sub.9为氢、甲基或乙基，R.sub.10为氢，n为0或1，条件是（a）当n为0时，R.sub.8也可以是甲基；（b）当n为1，且R.sub.7为氢，R.sub.9为氢或甲基时，R.sub.10也可以是甲基；（c）当R.sub.1为氢，R.sub.2为甲基，R.sub.3为氢，R.sub.6为甲基，R.sub.7为氢，R.sub.8为氢，n为0时，R.sub.4只能是乙氧基或丙氧基；（d）当R.sub.1为氢，R.sub.2为甲基，R.sub.3、R.sub.4、R.sub.7和R.sub.8为氢，n为0时，R.sub.6只能是甲氧基、乙氧基或乙基；以及其治疗上可接受的盐。已发现此类化合物在口服时可以成为有效的长效心脏抗心律失常药物。
• Novel therapeutic agents for membrane transporters
  申请人：——

  公开号：US20030044845A1

  公开（公告）日：2003-03-06

  Novel multi-binding compounds (agents) are disclosed which bind cell membrane transporters including ion channels, molecular transporters and ion pumps. The compounds of this invention comprise from 2 to 10 ligands each of which can bind to such cellular transporters to modulate the biological processes/functions thereof. Each of the ligands is covalently attached to a linker (framework) to provide for a multi-binding compound. The linker is selected such that the multi-binding compound exhibits increased modulation of the biological processes/functions of the transporter as compared to the aggregate of the individual ligand units made available for binding to the transporter.

  本发明揭示了一种新型多重结合化合物（试剂），其结合细胞膜转运体，包括离子通道、分子转运体和离子泵。本发明的化合物包括2到10个配体，每个配体都可以结合到这些细胞转运体上，以调节其生物过程/功能。每个配体都共价地连接到一个连接器（框架）上，以提供多重结合化合物。所选择的连接器是为了使多重结合化合物相比可用于结合转运体的单个配体单元的聚合体表现出增强的调节转运体的生物过程/功能的特性。
• Pharmaceutical local anesthetic composition employing saxitoxin
  申请人：Astra Pharmaceutical Products, Inc.

  公开号：US04001413A1

  公开（公告）日：1977-01-04

  A local anesthetic composition comprising a mixture in a pharmaceutically acceptable carrier of a particular toxin, namely, saxitoxin, and another compound, generally a conventional local anesthetic compound or a similar compound having nerve-blocking properties.

  一种局部麻醉剂组合物，包括一种特定的毒素——赛克替毒素和另一种化合物，通常是传统的局部麻醉剂化合物或具有神经阻滞性质的类似化合物，混合在药学可接受的载体中。
• Primary aminoacylanilides, methods of making the same and use as
  申请人：Astra Pharmaceutical Products, Inc.

  公开号：US04218477A1

  公开（公告）日：1980-08-19

  Primary amino acylanilides of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen, methyl, ethyl and propyl, R.sub.2 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.3 is selected from the group consisting of hydrogen and methyl, R.sub.4 is selected from the group consisting of hydrogen, methyl, and a C.sub.1 -C.sub.4 alkoxy group, R.sub.6 is selected from the group consisting of methyl, ethyl, chlorine, methoxy and ethoxy, R.sub.7 is hydrogen, methyl or ethyl, R.sub.8 is hydrogen, R.sub.9 is hydrogen, methyl or ethyl, R.sub.10 is hydrogen, and n is 0 or 1, with the provisions that (a) when n is 0, R.sub.8 can also be methyl; (b) when n is 1, and R.sub.7 is hydrogen, and R.sub.9 is hydrogen or methyl, then R.sub.10 can also be methyl; (c) when R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.6 is methyl, R.sub.7 is hydrogen, R.sub.8 is hydrogen, and n is 0, then R.sub.4 can be ethoxy or propoxy only; (d) when R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3, R.sub.4, R.sub.7 and R.sub.8 are hydrogen, and n is 0, then R.sub.6 is methoxy, ethoxy, or ethyl only; and the therapeutically acceptable salts thereof. Compounds of this type have been found to be effective longlasting cardiac antiarrhythmic agents, especially when administered by the oral route.

  式子为##STR1##其中R.sub.1选自氢、甲基、乙基和丙基的群组，R.sub.2选自甲基、乙基、氯、甲氧基和乙氧基的群组，R.sub.3选自氢和甲基的群组，R.sub.4选自氢、甲基和C.sub.1-C.sub.4烷氧基的群组，R.sub.6选自甲基、乙基、氯、甲氧基和乙氧基的群组，R.sub.7为氢、甲基或乙基，R.sub.8为氢，R.sub.9为氢、甲基或乙基，R.sub.10为氢，n为0或1，条件是(a)当n为0时，R.sub.8也可以是甲基；(b)当n为1时，且R.sub.7为氢，R.sub.9为氢或甲基时，R.sub.10也可以是甲基；(c)当R.sub.1为氢，R.sub.2为甲基，R.sub.3为氢，R.sub.6为甲基，R.sub.7为氢，R.sub.8为氢，n为0时，R.sub.4只能是乙氧基或丙氧基；(d)当R.sub.1为氢，R.sub.2为甲基，R.sub.3、R.sub.4、R.sub.7和R.sub.8均为氢，n为0时，R.sub.6只能是甲氧基、乙氧基或乙基；以及其治疗上可接受的盐。已发现这种化合物是有效的长效心脏抗心律失常药物，特别是通过口服途径给予。